Therapeutic Approach

Archive: June, 2015

Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering

LOS ANGELES, June 29, 2015 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the closing of its previously announced initial public offering of 4,000,000 shares […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD